Rapport Therapeutics, Inc. (RAPP) · Nov 4, 2026 · Earnings

Rapport Therapeutics earnings beat, but bipolar win is old news

Beat — GAAP EPS -$0.84 vs approximately -$1.20 consensus

Rapport Therapeutics’ Q3 earnings beat consensus and cash runway reaches 2029, but the key bipolar trial win was already disclosed.

Rapport is a clinical-stage neuroscience biotech advancing RAP-219 through Phase 3 epilepsy trials while preparing a bipolar-mania Phase 3 program. The bipolar Phase 2 success was already announced on October 20, 2026, so this filing mainly confirms that progress, reports the quarter, and updates the financing position.

The quarter beat the limited financial benchmark. GAAP diluted EPS was $0.84 per share in loss versus a published consensus of roughly $1.20 in loss, a meaningful beat, although the company remains loss-making and operating expenses rose as clinical programs advanced. The consensus estimate was publicly listed at approximately -$1.20 per share.

MetricQ3 2026Q3 2025Consensus
Net loss (Statement of Operations)$40.2M (+49.4%)-$26.9M
Diluted EPS (Statement of Operations)-$0.84-$0.71~-$1.20
R&D expense (Statement of Operations)$34.3M (+54.0%)$22.3M
Cash and short-term investments (Cash Position)$395.0M$436.1M*

*June 30, 2026 comparison.

The important clinical result is confirmation, not a fresh surprise. RAP-219 met both bipolar-mania Phase 2 endpoints, including a 3.1-point placebo-adjusted YMRS improvement, but that result was already public before this 8-K. 〔0〕 The filing does reinforce that the company is moving toward an FDA End-of-Phase 2 discussion in the first quarter of 2027 and two planned Phase 3 trials in the second half of 2027.

The balance sheet materially reduces near-term execution pressure. October’s equity-and-convertible-debt financing generated approximately $410.7 million of net proceeds, while the November ATM added approximately $10 million. Management now expects funding through the end of 2029, giving Rapport room to run the FOS Phase 3 program, prepare bipolar Phase 3, and advance earlier pipeline assets. 〔1〕

The trade-off is higher spending and capital usage as the pipeline scales. Net loss increased to $40.2 million from $26.9 million a year earlier, while R&D rose to $34.3 million from $22.3 million as FOS Phase 3 and bipolar development progressed. That is expected for the company’s stage, but it means the financing—not internal cash generation—is what extends the runway.

Bottom line: This is a modestly positive earnings update because the loss was narrower than consensus and funding now reaches 2029. It does not materially upgrade the clinical story, because the main bipolar win was already disclosed; the next genuinely new test is the FDA interaction in early 2027.

What to watch next

FDA End-of-Phase 2 meeting, Q1 2027

Original filing on SEC EDGAR

More Rapport Therapeutics, Inc. news

Rapport Therapeutics earnings beat, but bipolar win is old news | RAPP Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.